Literature DB >> 25132779

Diagnostic value of controlled attenuation parameter for liver steatosis in patients with chronic hepatitis B.

Chun-Yan Wang1, Wei Lu1, Dong-Sheng Hu1, Guang-Dong Wang1, Xiao-Jing Cheng1.   

Abstract

AIM: To study the diagnostic value of controlled attenuation parameter (CAP), evaluated by transient elastography, for liver steatosis in patients with chronic hepatitis B (CHB).
METHODS: Eighty-eight patients with CHB were enrolled in this study. All of the patients were subjected to transient elastography to determine CAP. These patients also underwent liver biopsy in the same period. Using liver biopsy as a reference, we determined receiver operating characteristic (ROC) curves for different endpoints. Areas under the ROC curves (AUCs) were used to evaluate the diagnostic importance of CAP for liver steatosis in patients with CHB.
RESULTS: A positive correlation was observed between the AUCs of CAP and liver pathological stage (r = 0.582, P < 0.05). CAP was not correlated with inflammation degree and fibrosis degree (r = -0.025, P > 0.05; r = 0. 068, P > 0.05). The mean CAP value at S0 was 209.59 ± 41.25 dB/m, 223.84 ± 35.28 dB/m at S1, 274.17 ± 43.69 dB/m at S2, and 312.50 ± 25.44 dB/m at S3. CAP values among S0, S1, S2, and S3 were significantly different (F = 17.79, P < 0.01). The AUC values for CAP were 0.711 (0.592-0.870), 0.868 (0.748-0.989), and 0.974 (0.922-1.026) for S1, S2, and S3, respectively. The optimal cut-off values were 219.5, 230.0, and 283.5 dB/m.
CONCLUSION: CAP is a novel tool that can be used to assess the degree of steatosis.

Entities:  

Keywords:  Chronic hepatitis B; Controlled attenuation parameter; Liver steatosis; Transient elastography

Mesh:

Year:  2014        PMID: 25132779      PMCID: PMC4130870          DOI: 10.3748/wjg.v20.i30.10585

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  20 in total

1.  Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology.

Authors:  A Grant; J Neuberger
Journal:  Gut       Date:  1999-10       Impact factor: 23.059

Review 2.  Alcoholic liver disease (ALD): a new domain for prevention efforts.

Authors:  Steve Sussman; Clyde W Dent; Silvana Skara; Paride de Calice; Hide Tsukamoto
Journal:  Subst Use Misuse       Date:  2002       Impact factor: 2.164

Review 3.  Steatosis: co-factor in other liver diseases.

Authors:  Elizabeth E Powell; Julie R Jonsson; Andrew D Clouston
Journal:  Hepatology       Date:  2005-07       Impact factor: 17.425

4.  Prevalence of and risk factors for hepatic steatosis in Northern Italy.

Authors:  S Bellentani; G Saccoccio; F Masutti; L S Crocè; G Brandi; F Sasso; G Cristanini; C Tiribelli
Journal:  Ann Intern Med       Date:  2000-01-18       Impact factor: 25.391

5.  Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.

Authors:  Gioacchino Leandro; Alessandra Mangia; Jason Hui; Paolo Fabris; Laura Rubbia-Brandt; Guido Colloredo; Luigi E Adinolfi; Tarik Asselah; Julie R Jonsson; Antonina Smedile; Norah Terrault; Valerio Pazienza; Maria Teresa Giordani; Emiliano Giostra; Aurelio Sonzogni; Giuseppe Ruggiero; Patrick Marcellin; Elizabeth E Powell; Jacob George; Francesco Negro
Journal:  Gastroenterology       Date:  2006-05       Impact factor: 22.682

6.  Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.

Authors:  Jeffrey D Browning; Lidia S Szczepaniak; Robert Dobbins; Pamela Nuremberg; Jay D Horton; Jonathan C Cohen; Scott M Grundy; Helen H Hobbs
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

7.  Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.

Authors:  Victor de Lédinghen; Julien Vergniol; Juliette Foucher; Wassil Merrouche; Brigitte le Bail
Journal:  Liver Int       Date:  2012-07       Impact factor: 5.828

8.  Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies.

Authors:  Eduardo Fassio; Estela Alvarez; Nora Domínguez; Graciela Landeira; Cristina Longo
Journal:  Hepatology       Date:  2004-10       Impact factor: 17.425

9.  Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis.

Authors:  A J Czaja; H A Carpenter
Journal:  Gastroenterology       Date:  1993-12       Impact factor: 22.682

10.  Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group.

Authors:  J H Lefkowitch; E R Schiff; G L Davis; R P Perrillo; K Lindsay; H C Bodenheimer; L A Balart; T J Ortego; J Payne; J L Dienstag
Journal:  Gastroenterology       Date:  1993-02       Impact factor: 22.682

View more
  5 in total

Review 1.  Noninvasive assessment of alcoholic liver disease using unidimensional transient elastography (Fibroscan(®)).

Authors:  Monica Lupsor-Platon; Radu Badea
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

2.  Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population.

Authors:  Wah-Kheong Chan; Nik Raihan Nik Mustapha; Grace Lai-Hung Wong; Vincent Wai-Sun Wong; Sanjiv Mahadeva
Journal:  United European Gastroenterol J       Date:  2016-06-23       Impact factor: 4.623

Review 3.  Non-invasive diagnosis of hepatic steatosis.

Authors:  Christiane Stern; Laurent Castera
Journal:  Hepatol Int       Date:  2016-10-25       Impact factor: 6.047

4.  Controlled attenuation parameter for assessment of hepatic steatosis grades: a diagnostic meta-analysis.

Authors:  Yuee Wang; Qingqi Fan; Ting Wang; Jia Wen; Hong Wang; Tiansong Zhang
Journal:  Int J Clin Exp Med       Date:  2015-10-15

5.  Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease.

Authors:  Cristina Margini; Giuseppe Murgia; Guido Stirnimann; Andrea De Gottardi; Nasser Semmo; Stefania Casu; Jaime Bosch; Jean-François Dufour; Annalisa Berzigotti
Journal:  Hepatol Commun       Date:  2018-07-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.